Ticker Details
Arcutis Biotherapeutics, Inc.
IPO Date:	January 31, 2020
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$3.15B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.62 | 3.55%
Avg Daily Range (30 D):	$0.78 | 2.84%
Avg Daily Range (90 D):	$0.68 | 2.72%

Institutional Daily Volume
Avg Daily Volume:	1.16M
Avg Daily Volume (30 D):	1.21M
Avg Daily Volume (90 D):	1.32M

Trade Size
Avg Trade Size (Sh.):	95
Avg Trade Size (Sh.) (30 D):	68
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	2,646
Avg Institutional Trade:	$2.37M
Avg Institutional Trade (30 D):	$3.34M
Avg Institutional Trade (90 D):	$3.35M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.26M
Avg Closing Trade (30 D):	$7.29M
Avg Closing Trade (90 D):	$7.42M
Avg Closing Volume:	212.53K

News

Aug 6, 2026 @ 12:30 PM Arcutis President and CEO Todd Watanabe Sells 4,37... Source: Sarah Sidlow

Jul 16, 2026 @ 1:00 PM Arcutis Expands Board of Directors with Appointmen... Source: Na

Jun 29, 2026 @ 11:06 PM FDA Approves Arcutis’ ZORYVE® (roflumila... Source: Arcutis Biotherapeutics, Inc.

Jun 23, 2026 @ 11:15 PM Arcutis Director Sells $121,000 in Stock as ZORYVE... Source: Jonathan Ponciano

Jun 9, 2026 @ 11:00 AM Antag Therapeutics Elects Keith Leonard as Chairma... Source: Not Specified

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$.21	$.11	$-.09
Diluted EPS	$.21	$.11	$-.09
Revenue	$463.98M	$129.86M	$105.4M
Gross Profit	$422.89M	$118.92M	$95.61M
Net Income / Loss	$28.52M	$15.01M	$-11.3M
Operating Income / Loss	$34.25M	$16.43M	$-9.09M
Cost of Revenue	$41.1M	$10.94M	$9.78M
Net Cash Flow	$-38.42M	$-.6M	$-8.03M
PE Ratio